GlassScriptPhysician profile
Inoel Rivera-Ramirez
NPI 1811984131
$8,115.76
in general payments reported to CMS, 2019-2025
48 companies · $1,015 in 2025
The $1,015 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $97.97 · 2020: $1,148 · 2021: $1,177 · 2022: $653 · 2023: $1,618 · 2024: $2,406 · 2025: $1,015.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,254 · Travel and Lodging: $1,784.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,254.32 |
| Travel and Lodging | $1,784.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,531.40 | 2021-2025 | Signia, Ligasure, Sonicision |
| Intuitive Surgical, INC. | $975.64 | 2019-2023 | Da Vinci Surgical System |
| Medical Device Business Services, INC. | $750.00 | 2020 | |
| Myriad Genetic Laboratories, INC. | $629.36 | 2021-2025 | Prolaris, Myrisk |
| Ferring Pharmaceuticals INC. | $472.64 | 2024-2025 | Adstiladrin |
| Astellas Pharma US INC | $462.50 | 2020-2023 | Myrbetriq |
| Coloplast Corp | $412.96 | 2020-2023 | Speedicath |
| Urogen Pharma, INC. | $348.72 | 2021-2025 | Jelmyto |
| Janssen Biotech, INC. | $271.01 | 2021-2025 | Erleada, Akeega |
| Endo Pharmaceuticals INC. | $260.27 | 2020-2023 | Aveed, Xiaflex |
| Dendreon Pharmaceuticals LLC | $205.99 | 2020-2024 | Provenge |
| Myovant Sciences INC. | $189.43 | 2021-2022 | |
| Blue Earth Diagnostics | $174.30 | 2021-2024 | |
| Pfizer INC. | $145.64 | 2019-2025 | |
| Abbvie INC. | $131.96 | 2022-2025 | Lupron Depot |
Show all 46 companies
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Inoel Rivera-Ramirez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.